How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies
Blincyto (Blinatumomab) is the first bispecific antibody construct from Amgen’s BiTE proprietary platform to be…
01/12/2015 - 3 minutes
Blincyto (Blinatumomab) is the first bispecific antibody construct from Amgen’s BiTE proprietary platform to be…